Partial replicate design and FDA ABE code [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2010-04-28 11:47 (5892 d 10:32 ago) – Posting: # 5252
Views: 41,828

Hi Dave,

❝ ❝ D. Labes:

❝ ❝ BTW: What is missing is explicit code for ABE evaluation for the partial replicate design ...


❝ The explicit code for this is on the last page (page 9) of the progesterone guidance. It's just the unscaled approach. You can use that method for both 4-period and 3-period designs.

(underlined by me)

I do not believe that. We have experimented with the FDA code on partial replicate design here in the forum and got some strange results. See f.i. here and here.
IMHO this is due to the fact that the intra-subject variance for Test is not identifiable in this design.


BTW: Regarding the sample size question of my very dear friend KR have a look into this tread.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
104 visitors (0 registered, 104 guests [including 14 identified bots]).
Forum time: 22:20 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5